CPT code 86408: COVID-19 antibody, neutralizing antibody screen2026 Medicare lab fee · Clinical Laboratory Fee Schedule
This screening test detects SARS-CoV-2 neutralizing antibodies and is reported for screening rather than neutralizing-antibody titer or general quantitative antibody measurement.
Medicare pays $42.13 for 86408 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$42.13
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2023
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 86408 covers
86408 identifies a laboratory screen for SARS-CoV-2 neutralizing antibodies. Report it when the service screens for these antibodies rather than measuring and reporting a neutralizing-antibody titer. Code 86409 represents the corresponding titer service, while 86413 represents quantitative SARS-CoV-2 antibody testing; these distinctions separate a neutralizing screen from titer or quantitative antibody reporting.
Medicare pays 86408 only through the Clinical Laboratory Fee Schedule (CLFS); it is excluded from physician fee schedule payment. The 2026 national CLFS amount is $42.13, applying in every state and locality with no geographic or office-versus-facility adjustment. The national amount was also $42.13 in 2023, 2024, and 2025. Report 86408 for screening; use 86409 when a neutralizing-antibody titer is measured and reported.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 86408
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 86408. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Excluded from the physician fee schedule
The physician fee schedule lists 86408 with status X (excluded by statute), so the test itself is paid only from the CLFS.
86408 on the lab fee schedule since 2020
86408 · CLFS 2026 Q4 (current)
$42.13
Unchanged since Jan 1, 2023
Every change on file
- Jan 1, 2023 · CLFS 2023 Q1MAC-priced → $42.13
25 quarterly CLFS releases on file, first CLFS 2020 Q4. A code missing from a quarter wasn’t on that release.
86408 compared with similar tests
- 86409Neutralizing antibodySARS-CoV-2 titer$79.61
- Choose 86408 for neutralizing-antibody screening and 86409 when a neutralizing-antibody titer is measured and reported.
- 86413COVID-19 antibodyQuantitative measurement$51.43
- 86413 represents quantitative SARS-CoV-2 antibody testing; 86408 is specifically a screen for neutralizing antibodies.
- 86769COVID-19 antibodyMultiple-step method$42.13
- 86769 describes SARS-CoV-2 antibody testing by a multiple-step method, rather than a neutralizing-antibody screen.
- 86328COVID-19 antibodySingle-step immunoassay$45.28
- 86328 describes SARS-CoV-2 antibody testing by a single-step method; 86408 identifies neutralizing-antibody screening.
86408 billing questions
How does 86408 differ from 86409?
86408 is for screening for SARS-CoV-2 neutralizing antibodies. Use 86409 when the service measures and reports a neutralizing-antibody titer.
Is 86408 the code for any SARS-CoV-2 antibody test?
No. It identifies a screen for neutralizing antibodies; 86413 represents quantitative SARS-CoV-2 antibody testing.
How does 86408 differ from 86328 and 86769?
86408 is specific to neutralizing-antibody screening. 86328 describes a single-step antibody method, while 86769 describes a multiple-step method.
Does Medicare pay 86408 under the physician fee schedule?
No. Medicare pays 86408 through the CLFS, and the same national amount applies across localities and settings.
Does 86408 include a separately payable physician interpretation?
86408 is paid only through the CLFS and is excluded from physician fee schedule payment.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 86408 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist